Amneal reports positive interim results for Parkinson's drug CREXONT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
June 5, 2026 8:00 AM EDTPhase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsSubstantial increases in daily Good On time, reductions in Off time, and meaningful improvements in motor function were observed after switching to CREXONT®Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily Good On time and nearly doubled the duration of continuous Good On intervals, enabling longer, uninterrupted periods of symptom control
BRIDGEWATER, N.J., June 05, 2026 (GLOBE... More
